Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...
The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients with HER2-low or HER2-ultraow metastatic disease that progressed after endocrine therapy.
Enhertu (fam-trastuzumab deruxtecan-nxki) can cause side effects ... Throughout Enhertu treatment, your doctor will monitor you for ILD by ordering blood work and other tests, such as a CT scan.
One of the most notable studies compared trastuzumab deruxtecan ... particularly interstitial lung disease and pneumonitis, which necessitates careful monitoring[1][3][5]. In a broader context ...
In the DATROWAY arm, the interstitial lung disease (ILD ... diverse breast cancer tumor environment. With fam-trastuzumab deruxtecan-nxki, a HER2-directed ADC, AstraZeneca and Daiichi Sankyo ...
GlobalData on MSN4mon
Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trialPatritumab deruxtecan’s safety profile in the trial was in line with previous lung cancer studies, without any new safety ...
In the DATROWAY arm, the interstitial lung disease (ILD ... collaboration to jointly develop and commercialize fam-trastuzumab deruxtecan-nxki in March 2019 and DATROWAY in July 2020, except ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback